Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

标题
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
作者
关键词
Alirocumab, PCSK9, LDL-C, HeFH, Lipid therapy, Cholesterol, Maximally tolerated statin, Lipid lowering, Placebo-controlled, Double-blind
出版物
Journal of Clinical Lipidology
Volume 11, Issue 1, Pages 195-203.e4
出版商
Elsevier BV
发表日期
2016-12-28
DOI
10.1016/j.jacl.2016.12.004

向作者/读者发起求助以获取更多资源

Reprint

联系作者

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started